10-Q: Aquestive Therapeutics Reports Q2 2024 Results, Revenue Jumps on One-Time Gains
Quarterly Report
Aquestive Therapeutics saw a significant revenue increase in Q2 2024, driven by one-time gains, despite a decrease in manufacturing revenue.
Summary
- Aquestive Therapeutics reported a net loss of $2.7 million for the second quarter of 2024, compared to a net loss of $5.8 million in the same period last year.
- Total revenue for Q2 2024 was $20.1 million, a 52% increase from $13.2 million in Q2 2023, primarily due to one-time gains from terminated agreements.
- Manufacture and supply revenue decreased by 30% to $8.1 million, while license and royalty revenue increased by 658% to $11.2 million.
- Co-development and research fees increased by 510% to $756 thousand.
- For the six months ended June 30, 2024, the company reported a net loss of $15.6 million, compared to a net income of $2.3 million in the same period last year.
- Total revenue for the first six months of 2024 was $32.2 million, a 32% increase from $24.4 million in the first six months of 2023.
- The company's cash and cash equivalents stood at $89.9 million as of June 30, 2024, up from $23.9 million at the end of 2023.
- The company completed an underwritten public offering in March and April 2024, raising net proceeds of $72.9 million.
Sentiment
Score: 6
Explanation: The document presents a mixed picture. While the company has made significant progress in its clinical programs and has improved its cash position, it is still operating at a loss and faces significant risks. The one-time revenue gains are not sustainable, and the company's reliance on external financing is a concern. The sentiment is cautiously optimistic.
Positives
- The company's cash position has significantly improved due to recent equity offerings.
- Aquestive successfully launched Libervant for a specific pediatric patient group.
- The Anaphylm program is progressing with positive clinical trial results and a clear regulatory path.
- The company has secured a new ATM facility for future capital raising.
- The company has a diverse portfolio of licensed products generating revenue.
Negatives
- The company reported a net loss for both the three and six months ended June 30, 2024.
- Manufacture and supply revenue decreased by 30% in Q2 2024 compared to the same period last year.
- The company is still dependent on external financing to achieve its operating plan.
- The company faces challenges in overcoming orphan drug exclusivity for Libervant in older patient populations.
- The company has significant debt obligations.
Risks
- The company's ability to achieve profitability is not assured.
- The company is dependent on external financing to fund its operations.
- The company faces risks related to the regulatory approval process for its product candidates.
- The company faces risks related to the commercialization of its products.
- The company faces risks related to competition from other pharmaceutical companies.
- The company faces risks related to intellectual property rights and infringement claims.
- The company faces risks related to the market acceptance of its products.
- The company faces risks related to the manufacturing of its products.
- The company faces risks related to the loss of significant customers.
- The company faces risks related to the debt obligations.
Future Outlook
Aquestive plans to request a pre-NDA meeting with the FDA in the third quarter of 2024 and to commence the pediatric study for Anaphylm immediately after the pre-NDA meeting. The company expects to begin the NDA submission with the FDA in December 2024 and complete the NDA submission in the first quarter of 2025. If the FDA approves the NDA for Anaphylm, the company expects to initiate a launch the product at the end of 2025 or in the first quarter of 2026.
Management Comments
- The company is focused on advancing its product pipeline, including Anaphylm and AQST-108.
- The company is expanding its commercial activities for Libervant, including sales and distribution networks.
- The company is managing business costs to prepare for a potential decline in Suboxone revenue.
Industry Context
Aquestive operates in the pharmaceutical industry, focusing on innovative drug delivery technologies. The company's focus on alternative administration methods addresses unmet needs in the market. The company's products compete with traditional methods of drug delivery, such as injections and oral tablets. The company's success depends on its ability to obtain regulatory approvals and commercialize its products effectively.
Comparison to Industry Standards
- Aquestive's revenue growth in Q2 2024 is significantly higher than the average growth rate for pharmaceutical companies, primarily due to one-time gains.
- The company's net loss is consistent with other development-stage pharmaceutical companies that are investing heavily in R&D.
- The company's cash position is strong compared to other companies of similar size, due to recent equity offerings.
- The company's focus on innovative drug delivery technologies is a differentiator in the market.
- The company's reliance on a few key customers for revenue is a risk factor that is common in the pharmaceutical industry.
Legal Proceedings
- The company is involved in several legal proceedings, including patent-related litigation, product liability lawsuits, and a lawsuit related to the approval of Libervant.
- The company is not able to determine or predict the ultimate outcome of these proceedings or provide a reasonable estimate of the possible loss, if any.
Stakeholder Impact
- Shareholders: The company's stock price may be affected by the company's financial performance and the progress of its clinical programs.
- Employees: The company's financial stability and growth prospects may affect employee morale and job security.
- Customers: The company's ability to commercialize its products may affect the availability of new treatment options.
- Suppliers: The company's financial stability may affect its ability to pay its suppliers.
- Creditors: The company's debt obligations may affect its ability to access future financing.
Next Steps
- The company plans to request a pre-NDA meeting with the FDA for Anaphylm in the third quarter of 2024.
- The company plans to commence the pediatric study for Anaphylm immediately after the pre-NDA meeting.
- The company expects to begin the NDA submission with the FDA in December 2024 and complete the NDA submission in the first quarter of 2025.
- The company plans to expand its commercial activities for Libervant, including sales and distribution networks.
Key Dates
| Date | Description |
|---|---|
| 2016-04-01 | Aquestive entered into a license agreement with Sunovion Pharmaceuticals Inc. |
| 2017-09-24 | Aquestive entered into a supplemental agreement with Indivior. |
| 2019-07-15 | Aquestive completed a private placement of 12.5% Senior Secured Notes. |
| 2019-09-01 | Aquestive established its first ATM facility. |
| 2019-12-05 | Neurelis Inc. filed a lawsuit against Aquestive Therapeutics, Inc. |
| 2020-11-03 | Aquestive entered into a Monetization Agreement with Marathon. |
| 2022-03-03 | Aquestive entered into the Haisco Agreement. |
| 2022-04-12 | Aquestive entered into the Lincoln Park Purchase Agreement. |
| 2022-05-03 | Aquestive filed a demurrer challenge to the sufficiency of the allegations of the Second Amended Complaint in the Neurelis lawsuit. |
| 2022-06-01 | Aquestive entered into Securities Purchase Agreements with certain purchasers. |
| 2022-09-26 | Aquestive entered into the Pharmanovia Agreement. |
| 2022-10-26 | Aquestive entered into the Assertio Agreement. |
| 2023-03-02 | Aquestive and Indivior entered into the Indivior Agreement to the Indivior License Amendment. |
| 2023-03-27 | Aquestive amended the Pharmanovia Agreement. |
| 2023-08-01 | Aquestive entered into the Letter Agreement with the Exercising Holder of the remaining warrants. |
| 2023-11-01 | Aquestive issued $45,000 aggregate principal amount of its 13.5% Notes due 2028. |
| 2024-03-22 | Aquestive completed the Underwritten Public Offering. |
| 2024-04-03 | Aquestive filed a new shelf registration statement on Form S-3. |
| 2024-04-22 | Aquestive sold additional shares of Common Stock pursuant to the partial exercise of the underwriters' option. |
| 2024-04-23 | The 2024 Registration Statement was declared effective by the SEC. |
| 2024-04-26 | The FDA approved Libervant for U.S. market access for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity in patients with epilepsy between two and five years of age. |
| 2024-06-01 | Aquestive and MTPA mutually agreed to terminate the MTPA Licensing Agreement. |
| 2024-06-03 | Aquestive and Haisco mutually agreed to terminate the Haisco Agreement. |
| 2024-07-29 | Aquestive was named as a defendant in over 560 product liability lawsuits. |
Keywords
Aquestive Therapeutics, Libervant, Anaphylm, epinephrine, pharmaceuticals, revenue, clinical trials, FDA, licensing, manufacturing, CNS, seizures, allergy, equity offering, debt
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.